Immutep Limited (ASX: IMM; NASDAQ: IMMP) ("Immutep“or “the Company”), a biotechnology company developing novel immunotherapy treatments forcancer and autoimmune diseases, is pleased to announce that it has received a €2,173,454 (~A$3,630,000) research and development (R&D) tax incentive payment in cash from the FrenchGovernment under its Crédit d’Impôt Recherche scheme (CIR).
For more information, please download the attached PDF
Download this document
